Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6124853 | Osteoarthritis and Cartilage | 2016 | 12 Pages |
Abstract
Work is continuing on testing biomarkers in OA. There is still a huge, unmet medical need to identify, test, validate and qualify novel and well-known biomarkers. A pre-requisite for this is better characterization and classification of biomarkers to their needs, which may not be reached before higher understanding of OA phenotypes has been gained. In addition, we provide some references to some recent guidelines from Food and Drug Administration (FDA) and European Medicines Agency (EMA) on qualification and usage of biomarkers for drug development and personalized medicine, which may provide value to the field.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
A.C. Bay-Jensen, D. Reker, C.F. Kjelgaard-Petersen, A. Mobasheri, M.A. Karsdal, C. Ladel, Y. Henrotin, C.S. Thudium,